H.C. Wainwright raises target for Relay Therapeutics stock to USD 29

Published on 10/16/2026 at 04:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The October 6 filing covered 93,153 shares worth USD 1.81 million. For Relay Therapeutics stock, cash stood at USD 911 million.

Insider filing and pipeline data

Thomas Catinazzo filed notice of a proposed 93,153-share sale on October 6, 2026.
Relay reported 60 percent volumetric response in vascular anomalies on September 16, 2026.
Relay Therapeutics had a USD 3.8 billion market capitalization as of October 15, 2026.

RLAY, US75943R1023, Illustration mit AI erstellt.

Relay Therapeutics (ISIN US75943R1023) disclosed a proposed sale of 93,153 common shares valued at USD 1.81 million in a filing dated October 6, 2026. Investing.com reported that H.C. Wainwright raised its target for Relay Therapeutics to USD 29 while keeping a Buy rating. The source did not give the earlier target.

Three dates shape the story

MarketBeat reported that Relay's second-quarter results on August 6, 2026 included a USD 0.35 million revenue figure and a USD 0.41 loss per share against a USD 0.39 consensus loss. The miss gives the analyst target a demanding earnings backdrop.

At the Morgan Stanley healthcare conference on September 16, 2026, management described USD 911 million of cash at the end of the second quarter and said it supported operations into 2029. Investing.com also reported a 60 percent volumetric response rate in vascular anomalies.

Finally, the October 6, 2026 Form 144 notice covered 93,153 shares and listed 219,141,631 common shares outstanding. Stock Titan identified Thomas Catinazzo as the officer involved and NASDAQ as the named exchange.

What does USD 911 million mean?

The cash balance is the central counterweight to the second-quarter loss. Relay is directing much of that capital toward three registrational programs, including breast cancer and vascular anomaly studies, while preparing a Phase 3 first-line breast cancer trial for early 2027 pending regulatory feedback, according to the September 16 conference report.

Valuation carries a clinical risk

Relay Therapeutics had a market capitalization of USD 3.8 billion as of October 15, 2026. Its 52-week range was USD 5.95 to USD 21.27 on the same date. The company remains a clinical-stage biotechnology business, so the USD 29 target depends on trial execution, regulatory progress and the conversion of clinical data into approved products.

Cash supports the pipeline

Relay's financial position gives management room to advance several programs, but the August revenue and earnings figures show that commercial results remain distant. The combination of a USD 911 million cash balance and a USD 29 analyst target places clinical milestones ahead of near-term sales as the key valuation reference.